These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 15816878

  • 1. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.
    Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T.
    Am J Transplant; 2005 May; 5(5):987-94. PubMed ID: 15816878
    [Abstract] [Full Text] [Related]

  • 2. Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus.
    El-Sheikh AA, Koenderink JB, Wouterse AC, van den Broek PH, Verweij VG, Masereeuw R, Russel FG.
    Transl Res; 2014 Jul; 164(1):46-56. PubMed ID: 24486136
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
    van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE.
    Ther Drug Monit; 2001 Apr; 23(2):119-28. PubMed ID: 11294511
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats.
    Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T.
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1029-35. PubMed ID: 14978191
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication.
    Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM.
    Ther Drug Monit; 2002 Oct; 24(5):598-606. PubMed ID: 12352931
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 8. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice.
    Wang J, Figurski M, Shaw LM, Burckart GJ.
    Transpl Immunol; 2008 Jul; 19(3-4):192-6. PubMed ID: 18586494
    [Abstract] [Full Text] [Related]

  • 9. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 10. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [Abstract] [Full Text] [Related]

  • 11. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 12. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 13. Influence of metal cations on plasma trough concentration of mycophenolic Acid and its glucuronide in tacrolimus-treated and cyclosporine-treated kidney transplant recipients.
    Naito T, Mino Y, Otsuka A, Ushiyama T, Ozono S, Kagawa Y, Kawakami J.
    Biol Pharm Bull; 2008 Jun; 31(6):1292-6. PubMed ID: 18520072
    [Abstract] [Full Text] [Related]

  • 14. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
    Clin Pharmacokinet; 2009 Jun; 48(11):745-58. PubMed ID: 19817503
    [Abstract] [Full Text] [Related]

  • 15. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 16. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.
    Heller T, van Gelder T, Budde K, de Fijter JW, Kuypers D, Arns W, Schmidt J, Rostaing L, Powis SH, Claesson K, Macphee IA, Pohanka E, Engelmayer J, Brandhorst G, Oellerich M, Armstrong VW.
    Am J Transplant; 2007 Jul; 7(7):1822-31. PubMed ID: 17532750
    [Abstract] [Full Text] [Related]

  • 17. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
    Morissette P, Albert C, Busque S, St-Louis G, Vinet B.
    Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
    [Abstract] [Full Text] [Related]

  • 18. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE, Tett SE.
    Clin Pharmacokinet; 2007 Oct; 46(1):13-58. PubMed ID: 17201457
    [Abstract] [Full Text] [Related]

  • 19. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
    Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, Kagawa Y, Kawakami J.
    J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
    [Abstract] [Full Text] [Related]

  • 20. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.